Editorial companion generated in the 1.0.1 session. Study confirmation requests concern clinical research use; this is published as a demonstration.
The delivered manuscript is a complete review draft of the ClinicalSpark demonstration, not an independently validated clinical study or a journal submission. Its scientific limits are stated in the manuscript itself. The collective author label is retained from the input; no affiliation, contact, funding, approval, registration or author contribution has been invented. Tables 1–8 are in tables.docx and tables.md to follow the supplied house convention of separate tables. The Markdown source uses cite-keys linked to references.yaml; the house assembler generates numbered references in Word.
Supply the provenance of the demonstration values and determine whether they are real-record outputs, simulated examples or a mixture. If clinical research is intended, provide the protocol, geographic setting, calendar period, institutional review and data-use documentation; cohort eligibility and flow; de-identified analysis provenance; code lists; linkage rules; missing-data handling; exposure/outcome validation; event counts; person-time and censoring; full model formulas and references; executable analyses; software versions; and patient-level development/evaluation split evidence. Confirm author identities, affiliations, correspondence, roles, funding and competing interests. The draft’s two alternative target journals do not constitute a selected venue, and no claim of compliance with either journal’s current submission instructions is made.
These calculations check printed values only. They are not a reanalysis and cannot establish which source result is correct.
| Issue | Check of supplied values | Required evidence |
|---|---|---|
| Cohort sum | 2,816,907 + 585,518 + 18,352 = 3,420,777 | Counts are arithmetically consistent, but distinct classifications need independent derivation |
| Impaired matching population | 585,518 + 18,352 = 603,870 impaired; matched impaired n is 585,518 | Eligibility, unmatched counts and reasons; clarify why this equals the treated group |
| Repeated subgroup counts | Chewing/prosthetic counts recur as tooth-count categories; 585,518 and 18,352 recur as tooth-site denominators | Cross-tabulations and original group-construction code |
| Repeated HRs | 4.846 and CI 4.176–5.623 recur under unrestored impairment, molar loss and severe tooth loss | Independent model outputs and estimands |
| Product of HRs | 4.846 × 0.428 = 2.074088, essentially the anterior-loss HR 2.074 | Clarify whether values come from one coefficient coding scheme, derived effects or separate models |
| Crude mortality | 3.673 / 0.683 = 5.377745, not 4.846 | Do not equate a crude risk ratio with a Cox HR; define each observation period |
| Survival vs crude mortality | 100 − 97.4 = 2.6%; 100 − 84.2 = 15.8%, versus crude 0.683% and 3.673% | Follow-up, group mapping, event times and censoring can explain differences but are unavailable |
| Age SMD | (58.4 − 54.2)/sqrt((10.1² + 9.2²)/2) ≈ 0.435, versus 0.384 supplied | Unrounded statistics and exact SMD definition |
| Sex SMD | (0.542 − 0.518)/sqrt((0.542×0.458 + 0.518×0.482)/2) ≈ 0.048, versus 0.112 supplied | Same |
| Other SMDs | Printed SBP summaries give ≈0.147 versus 0.151; BMI ≈0.006 versus 0.003 | Smaller differences may involve rounding or a different convention |
| Diabetes percentages | 2,560/18,352 = 13.9494%; 59,485/585,518 = 10.1594% | Printed prevalences round correctly |
| Diabetes RR comparator | Printed prevalences/RRs imply approximately 7.962% and 7.498% reference prevalence | Specify whether ratios are adjusted or use different reference groups; cannot verify one crude common control |
| Tooth-site HR ratio | 4.846/2.074 ≈ 2.3365 | No valid direct-comparison P or CI can be inferred from the two marginal intervals |
| Mediation components | 0.0283 + 0.0071 + 0.0058 = 0.0412; indirect sum = 0.0129 | Algebra is consistent; effect scale and identification remain unspecified |
| Mediation percentages | Printed coefficients imply 68.69%, 17.23%, 14.08%, and 31.31% total indirect, versus 68.6%, 17.2%, 14.2%, 31.4% supplied | Unrounded estimates could reconcile; original percentages are retained and flagged |
| Survival difference | 97.4 − 84.2 = 13.2 percentage points; relative decline is 13.55% | Corrected wording; no new clinical inference |
| Feature importance | Six importances sum to 100%; molar loss plus chewing difficulty sums to 48.1% | Define importance metric; these values are not causal contribution |
| F1 consistency | If sensitivity 0.784, specificity 0.761 and positive-class binary F1 0.749 are from one sample/threshold, implied event prevalence is about 43.6% | Supply class prevalence, confusion matrix, threshold and averaging convention; this conditional check is not evidence of error |
Table 2 inferential summaries are transcribed but have not been recomputed. Their z, HR, CI and P consistency must be checked against original model output rather than certified by the transcription audit. No unsupported direct-contrast P value was created. All source analytical categories are covered in Results and their detailed tables; unsupported biological narratives and policy recommendations were removed rather than silently converted into evidence.
The revised manuscript uses five directly relevant supplied clinical papers and three reporting statements, with all bibliographic metadata fetched by the frozen Crossref/PubMed verifier. The input’s generic study-group authors and several bibliographic details were inaccurate. Registry metadata replace them: Tay et al. is the 2026 volume 105(1):95–102 paper, Abe et al. is pages 1553–1562, Hamrah et al. is article 95, Fushida et al. has a different verified title, and Marito et al. has a different verified title. The Suita correction concerns a missing grant number and explicitly states that scientific conclusions are unchanged.
Input references 2, 6, 7, 9 and 10 were not retained because the revised argument does not need them. They are not certified as invalid or retracted. Source 6’s DOI was found to refer to a chewing/swallowing and frailty study with a different title from that supplied. Detailed trigeminal, inflammatory, short-chain-fatty-acid, occlusal-force and airway claims were removed because the available demonstration material did not establish those mechanisms. No earlier manuscript or sibling-run material was used.
| Framework / domain | Status in this review draft | Missing evidence |
|---|---|---|
| STROBE title, objectives, interpretation, limitations | Demonstration identity and interpretation boundaries explicit | Clinical-study identity still requires provenance |
| STROBE setting, eligibility, follow-up, participant flow | Unavailable details stated in Methods | Dates, setting, cohort construction, flow and numbers at risk |
| STROBE variables, bias and statistics | Available definitions transcribed; limitations explicit | Validation, complete adjustment, missing data, sensitivity analyses, multiplicity |
| RECORD codes, linkage and reproducibility | Source table names and broad outcome codes provided | Complete code lists, linkage validation, executable definitions and scripts |
| TRIPOD+AI model development | Algorithm and six reported variables described | Samples, tuning, hyperparameters, preprocessing, seeds and model object |
| TRIPOD+AI evaluation | Metrics transcribed with explicit validation limits | Test data, discrimination uncertainty, calibration, external evaluation, utility |
| Ethics and declarations | No fabricated approval or negative conflict assertion | Responsible authors’ actual declarations and institutional documentation |
Full guideline compliance and clinical reproducibility remain unestablished; a reporting checklist cannot supply missing study facts.